CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention FFR-guided multivessel stenting reduces urgent revascularization compared with infarct-related artery only stenting in ST-elevation myocardial infarction: A meta-analysis of randomized controlled trials Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing JACC Scientific Expert Panel A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion Characterization of lesions undergoing ischemia-driven revascularization after complete revascularization versus culprit lesion only in patients with STEMI and multivessel disease - A DANAMI-3-PRIMULTI substudy Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents

Original Research10 June 2020

JOURNAL:Catheter Cardiovasc Interv. Article Link

Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement

J Sathananthan, P Green, M Finn et al. Keywords: -min walk test; aortic stenosis; TAVR

ABSTRACT

BACKGROUND - While slow gait speed is known to be associated with poor outcomes in patients at high surgical risk who undergo transcatheter aortic valve replacement (TAVR), the prognostic significance of slow gait speed in intermediate risk TAVR patients is poorly understood.

 

OBJECTIVES - We assessed the association between baseline 6min walk test (6MWT) performance and both 2year mortality and health status in intermediate risk patients undergoing TAVR as a part of the PARTNER II/S3i studies.

 

METHODS - The association of baseline 6MWT with mortality over 2years after TAVR was examined using Cox regression; both unadjusted and adjusted for age, left ventricular ejection fraction, coronary artery disease, pulmonary disease, renal insufficiency, and STS score. Patients were divided into four groups according to baseline 6MWT: unable to walk and in three equal tertiles of slow, medium, and fast walkers. Among surviving patients, improvement in 6MWT and quality of life were compared.

 

RESULTS - Among 2,037 intermediate risk TAVR patients (mean age 81.7 years, STS score 5.6%), 8.2% were unable to walk. Baseline 6MWT was associated with allcause mortality over 2 years (Hazard ratio (HR) 0.87 per 50 m, 95% confidence interval [CI] 0.83 to 0.92, p < .0001). Among surviving patients, the adjusted absolute change in 6MWT at 2 years improved for patients unable to walk (+134.1 m, 95% CI 102.1 to 166 m, p < .0001) and slow walkers (+60.5 m, 95% CI 42.8 to 78.2 m, p < .0001), but was unchanged for medium walkers (7.3 m, 95% CI 24.3 to 9.6 m, p = .4), and declined for fast walkers (41.3 m, 95% CI 58.7 to 23.9 m, p < .0001).

 

CONCLUSION - Poor functional capacity is predictive of 2year mortality in elderly intermediate risk patients undergoing TAVR. However, surviving patients with poor baseline functional capacity had significant improvement in 6MWT performance and quality of life at 2years following TAVR.